Latest Conference Articles

Tarlatamab-dlle shows significant overall survival benefits over chemotherapy in small cell lung cancer, even in platinum-resistant cases.

BNT111 combined with cemiplimab shows promising efficacy in treating PD-(L)1-relapsed melanoma, achieving significant response rates and manageable safety profiles.

The COMPETE trial reveals ITM-11 significantly improves progression-free survival and overall response rates in GEP-NET patients compared with everolimus.

Tarlatamab combined with frontline chemoimmunotherapy shows promising safety and efficacy in extensive-stage small cell lung cancer patients.

XTR008 therapy shows significant benefits in treating GEP-NETs, enhancing survival rates and quality of life compared to octreotide LAR.

Giredestrant combined with everolimus significantly enhances progression-free survival in advanced ER-positive breast cancer, offering a promising new treatment option.

Fruquintinib plus sintilimab significantly enhances progression-free survival in advanced renal cell carcinoma, offering a promising second-line treatment option.

Pimicotinib shows promising long-term efficacy in treating tenosynovial giant cell tumor, achieving high response rates and durable outcomes in patients.

Regorafenib and nivolumab show promising results in advanced gastric cancer, offering improved response rates and quality of life compared to chemotherapy.

Combination therapy of osimertinib and chemotherapy significantly enhances overall survival in patients with EGFR-mutated advanced lung cancer, surpassing monotherapy outcomes.

Combining local consolidative therapy with osimertinib enhances progression-free survival in metastatic EGFR-mutant non-small cell lung cancer patients.

Ribociclib combined with aromatase inhibitors significantly enhances invasive disease-free survival in early breast cancer, offering lasting benefits beyond treatment.

Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone.

Alectinib shows promising long-term survival benefits over crizotinib in advanced ALK-positive lung cancer, highlighting significant clinical advancements.

Patients with metastatic hormone-sensitive prostate cancer report stable health-related quality of life while receiving niraparib and abiraterone acetate in the AMPLITUDE trial.

Lenvatinib combined with pembrolizumab and chemotherapy shows no significant survival benefit over pembrolizumab plus chemotherapy in metastatic esophageal cancer.

New findings reveal that adding durvalumab to chemotherapy enhances survival in muscle-invasive bladder cancer without harming quality of life.

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.

Durvalumab enhances disease-free survival in high-risk non-muscle invasive bladder cancer when combined with BCG therapy, according to recent trial results.

Sevabertinib shows promising efficacy in treating HER2-mutant advanced NSCLC, achieving high response rates and durable outcomes in clinical trials.

A phase 1/2 trial shows saruparib combined with ARPI offers high response rates and manageable safety in metastatic prostate cancer patients.

Anbenitamab plus chemotherapy significantly improves survival rates in HER2-positive gastric cancer patients, offering a promising new treatment option.

Durvalumab combined with FLOT chemotherapy significantly enhances overall survival in resectable gastric adenocarcinoma, establishing a new standard of care.

New research suggests using mpMRI for bladder cancer staging improves survival rates, potentially changing standard diagnostic practices.

Zongertinib shows promising results as a first-line treatment for advanced HER2-mutant NSCLC, achieving high response rates and significant clinical benefits.

A new treatment regimen for metastatic prostate cancer shows significant reductions in severe adverse events, offering a promising alternative for patients.

Dr. Joyce O'Shaughnessy discusses the monarchE trial's findings, emphasizing the importance of abemaciclib in reducing breast cancer recurrence and improving patient access.

Cevostamab delivered feasible and well-tolerated antitumor activities post CAR T-cell therapy in patients with heavily pretreated multiple myeloma.

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.